摘要
目的分析探讨前列地尔与腺苷蛋氨酸联合对病毒性肝炎高胆红素血症治疗效果及相关影响因素。方法选取2016年1月至2018年1月收治的90例病毒性肝炎合并高胆红素血症患者,随机分为对照组和观察组,每组45例。对照组单纯给予前列地尔药物进行治疗;观察组在对照组的基础上,加用腺苷蛋氨酸药物,采用静脉滴注的治疗方法,治疗4周后进行比对。结果观察组患者治疗效果明显优于对照组,差异有统计学意义(P<0.05)。治疗后观察组患者总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转氨酶(γ-GT)水平与对照组相比下降明显,有统计学意义(P<0.05);观察组患者在改善焦虑情绪反应方面差异有统计学意义(P<0.05)。结论腺苷蛋氨酸与前列地尔两种药物联合治疗病毒性肝炎高胆红素血症的方法,明显降低了TBIL水平,改善ALT、γ-GT等肝功能指标,有效提升了患者的临床疗效,同时,随着临床症状和体征减轻,患者焦虑情绪明显改善,值得在临床推广应用。
Objective To investigate the therapeutic effects and the related influencing factors of alprostadil combined with adenosylmethionine in treatment of viral hepatitis complicated by hyperbilirubinemia.Methods A total of 90 patients with viral hepatitis complicated by hyperbilirubinemia who were admitted and treated in our hospital from January 2016 to January 2018 were randomly divided into control group(n=45)and observation group(n=45).The patients in control group were treated by alprostadil only,however the patients in observation group,on the basis of control group,were treated by intravenous drip with adenosylmethionine.After 4-week treatment the therapeutic effects were observed and compared between the two groups.Results The therapeutic effects in observation group were superior to those in control group(P<0.05).After treatment,the levels of total bilirubin(TBIL),alanine aminotransferase(ALT),γ-glutamyl transaminase(γ-GT)in observation group were significantly lower than those in control group(P<0.05).There was significant difference in improving anxiety and emotional response between the two groups(P<0.05).Conclusion The ademethionine combined with alprostadil in treatment of viral hepatitis with hyperbilirubinemia can significantly reduce the levels of TBIL,improve the liver function indexes including ALT andγ-GT,which can effectively improve the clinical efficacy,therefor,which is worthy of clinical application and popularization.
作者
冯小涛
焦雨薇
赵欢
贾运乔
崔敬艳
FENG Xiaotao;JIAO Yuwei;ZHAO Huan(Department of Genneral Surgery,Hebei Provincial People’s Hospital, Hebei,Shijiazhuang 050051,China)
出处
《河北医药》
CAS
2020年第4期565-568,共4页
Hebei Medical Journal
